コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 d the general population using data from the Surveillance, Epidemiology and End Results Program.
2 c, and calendar-year-specific rates from the Surveillance, Epidemiology and End Results Program.
3 67 patients with CLL in the population-based Surveillance, Epidemiology and End Results Program.
4 (age 15 to 39 years) identified through the Surveillance, Epidemiology, and End Results Program.
5 ients were derived from the population-based Surveillance, Epidemiology, and End Results program.
6 GUS than in the white population of the Iowa Surveillance, Epidemiology, and End Results Program.
7 rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program.
8 Patient cases were sampled from within the Surveillance, Epidemiology, and End Results program.
9 egistries of the National Cancer Institute's Surveillance, Epidemiology, and End Results program.
10 the literature and mortality rates from the Surveillance, Epidemiology, and End Results Program.
11 mpared with the white population of the Iowa Surveillance, Epidemiology, and End Results program.
12 cancer registry data for 1973-1994 from the Surveillance, Epidemiology, and End Results program.
13 age-specific incidence rate patterns in the Surveillance, Epidemiology, and End-Results program.
14 e population-based National Cancer Institute Surveillance, Epidemiology, and End-Results program.
15 Data were obtained from the Surveillance, Epidemiology, and End Results program (197
16 obtained from the National Cancer Institute Surveillance, Epidemiology, and End Results program (197
17 nonseminoma reported to the population-based Surveillance, Epidemiology, and End Results program (198
18 nonseminoma reported to the population-based Surveillance, Epidemiology, and End Results program (198
19 Data from the Surveillance, Epidemiology, and End Results program (200
20 ed through linkage with pathology databases; Surveillance, Epidemiology, and End Results programs; an
21 unction and hazard ratio results, along with Surveillance, Epidemiology, and End Results program and
22 ho were listed in the linked database of the Surveillance, Epidemiology, and End Results program and
23 sed 1973-2000 data from the population-based Surveillance, Epidemiology, and End Results Program and
26 ed in 1 of the 10 study areas covered by the Surveillance, Epidemiology, and End Results Program, and
27 ence rate from the National Cancer Institute-Surveillance, Epidemiology, and End Results Program canc
28 e identified cancer cases via linkage to the Surveillance, Epidemiology, and End Results Program canc
29 cer cases (n = 262) were identified from the Surveillance, Epidemiology, and End Results Program canc
30 ta from 9 population-based registries of the Surveillance, Epidemiology, and End Results program coll
31 titute's Connecticut Historical Database and Surveillance, Epidemiology, and End Results program coll
33 han that reported in the general population (Surveillance, Epidemiology, and End Results Program data
34 sus and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for
35 ts with primary colon cancer reported to the Surveillance, Epidemiology and End Results Program from
36 e and cancer stage and grade observed in the Surveillance, Epidemiology, and End Results program in 2
37 mesothelioma incidence data released by the Surveillance, Epidemiology, and End Results Program in A
38 om population-based cancer registries in the Surveillance, Epidemiology, and End Results Program in t
39 Data sources included the Surveillance, Epidemiology, and End Results Program, Nat
40 ellness Survey; Nationwide Inpatient Sample; Surveillance, Epidemiology, and End Results Program; Nat
41 trospective analysis that used data from the Surveillance, Epidemiology, and End Results program of t
42 e US cancer population were derived from the Surveillance, Epidemiology, and End Results Program of t
43 ancer incidence rates based on data from the Surveillance, Epidemiology, and End Results Program of t
44 the nine population-based registries of the Surveillance, Epidemiology, and End Results Program of t
45 stracted from 83,686 cases registered in the Surveillance, Epidemiology, and End Results Program of w
46 nt data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program on i
47 linkage with a state cancer registry or the Surveillance, Epidemiology, and End Results program, or
48 fied by linkage to a pathology database, the Surveillance, Epidemiology, and End Results program, or
49 Data from nine Surveillance, Epidemiology, and End Results program regi
50 en (8387 MR examinations) linked to regional Surveillance, Epidemiology, and End Results program regi
51 The National Cancer Institute's Surveillance, Epidemiology, and End Results Program rele
52 (n = 204) and 9 US cancer registries of the Surveillance, Epidemiology, and End Results program (SEE
53 th 95% confidence intervals (CIs), using the Surveillance, Epidemiology, and End Results Program (SEE
54 ectal SRCC in a large patient group from the Surveillance, Epidemiology, and End Results program (SEE
55 By using Surveillance, Epidemiology, and End-Results program (SEE
56 ed with age-adjusted cancer incidence in the Surveillance, Epidemiology and End Results Program (SEER
57 were the Breast Cancer Prevention Trial, the Surveillance, Epidemiology, and End-Results program, tim
60 pulation-based cancer registry data from the Surveillance, Epidemiology, and End Results Program to M
62 Incidence data (1973-1992) from the Surveillance, Epidemiology, and End Results Program were
63 on data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program, whi
64 nuary 1, 1973, and December 31, 1996, in the Surveillance, Epidemiology, and End Results Program who
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。